Literature DB >> 10858386

Clinical predictors of N2 disease in non-small cell lung cancer.

K Takamochi1, K Nagai, K Suzuki, J Yoshida, Y Ohde, Y Nishiwaki.   

Abstract

OBJECTIVES: To identify clinical or radiologic predictors of mediastinal lymph node involvement in patients with non-small cell lung cancer, and to define the indications of preoperative mediastinoscopy.
METHODS: From August 1992 through April 1997, 387 patients with lung cancer (290 adenocarcinoma and 97 squamous cell carcinoma) underwent surgical resection. We retrospectively measured all mediastinal lymph node sizes both in the shortest and longest axes on contrast-enhanced CT scan to determine the optimal size criteria. Using multivariate logistic regression analysis, we identified clinical or radiologic predictors of N2 disease.
RESULTS: We could not identify reliable size criteria for nodal involvement. We found two significant predictive factors of N2 disease on the basis of multivariable analysis: maximum tumor dimension and serum carcinoembryonic antigen (CEA) concentrations. The lymph node size did not prove to be a significant factor. Among 50 patients with serum CEA concentrations < 5.0 ng/mL and maximum tumor dimension < 20 mm, pathologic N2 disease was proven only in three patients (6%), regardless of the lymph node size on CT scan. Among 140 patients with serum CEA concentrations > or = 5.0 ng/mL and maximum tumor dimension > or = 20 mm, approximately one third (n = 46) showed N2 disease.
CONCLUSION: Serum CEA concentrations and maximum tumor dimension were more valuable in predicting N2 disease than the lymph node size on CT scan. Mediastinoscopy is indicated in patients with serum CEA concentrations > or = 5.0 ng/mL and maximum tumor dimension > or = 20 mm, and not indicated in patients with serum CEA concentrations < 5.0 ng/mL and maximum tumor dimension < 20 mm.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858386     DOI: 10.1378/chest.117.6.1577

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Prognosis of surgically resected lung cancer with extremely high preoperative serum carcinoembryonic antigen level.

Authors:  Nobumasa Takahashi; Kenji Suzuki; Kazuya Takamochi; Shiaki Oh
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-10-08

2.  A Prediction Model to Help with the Assessment of Adenopathy in Lung Cancer: HAL.

Authors:  Oisin J O'Connell; Francisco A Almeida; Michael J Simoff; Lonny Yarmus; Ray Lazarus; Benjamin Young; Yu Chen; Roy Semaan; Timothy M Saettele; Joseph Cicenia; Harmeet Bedi; Corrine Kliment; Liang Li; Sonali Sethi; Javier Diaz-Mendoza; David Feller-Kopman; Juhee Song; Thomas Gildea; Hans Lee; Horiana B Grosu; Michael Machuzak; Macarena Rodriguez-Vial; George A Eapen; Carlos A Jimenez; Roberto F Casal; David E Ost
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

3.  Recursive Partitioning Analysis of Mediastinal N2 Lymph Node Involvement with Selected Biological Markers in Operable Non-small Cell Lung Cancer: A Correlative Study.

Authors:  H Bozcuk; A Gumus; G Ozbilim; A Sarper; I Kucukosmanoglu; M Ozdogan; A Demircan
Journal:  Biomark Insights       Date:  2007-10-06

4.  The impact on the prognosis of unsuspected N2 disease in non-small-cell lung cancer: indications for thorough mediastinal staging in the modern era.

Authors:  Ryosuke Tachi; Aritoshi Hattori; Takeshi Matsunaga; Kazuya Takamochi; Shiaki Oh; Kenji Suzuki
Journal:  Surg Today       Date:  2016-07-21       Impact factor: 2.549

5.  Morphometric analysis of regional lymph nodes in surgically resected non-small cell lung cancer.

Authors:  Hajimu Gotoh; Naoki Kanomata; Masahiro Yoshimura; Yoshiharu Ohno; Takuya Moriya; Chiho Ohbayashi
Journal:  Med Mol Morphol       Date:  2009-09-26       Impact factor: 2.309

6.  Preoperative predictors of lymph node metastasis in clinical T1 adenocarcinoma.

Authors:  Kenta Nakahashi; Nobuo Tsunooka; Kyo Hirayama; Masahiro Matsuno; Mareyuki Endo; Junichi Akahira; Masataka Taguri
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.